Disease modifying treatment available:
Time critical diagnosis and management:
Lateralising:
None
None
None
Myelin oligodendrocyte glycoprotein antibody disease may cause the following:
None
| Laboratory Investigation | Result |
|---|
Acute management of relapses utilises steroids, intravenous immunoglobulin and plasma exchange. Long term immunosuppression to reduce relapse rate is often achieved with rituximab, cyclophosphamide, azathioprine, MMF or tocilizumab.
None